Drug intelligence / Profile preview

ET0111

Development stage: Phase 1
Lead developer: ETERN Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ET0111 is an orally bioavailable small molecule inhibitor targeting fibroblast growth factor receptors (FGFRs). By binding to and inhibiting FGFRs, ET0111 blocks FGFR-mediated signal transduction pathways, which are implicated in the growth and survival of certain cancer cells. This mechanism confers potential antineoplastic activity. The drug is being developed by ETERN Therapeutics for the treatment of advanced malignant solid neoplasms and is currently undergoing Phase 1 clinical trials as monotherapy in patients with advanced solid tumors[1][2][3][7].

Other names: FGFR inhibitor ET0111

Targets

FGFR3 (Fibroblast growth factor receptor 3)

Beyond the preview

Go deeper on ET0111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ET0111.

Explore the full profile